Prediction of recurrent acute Ischemic Stroke based on Apolipoprotein B levels: a nested case-control study
Description
Background Mendelian randomization studies have identified that apolipoprotein B (ApoB) is the primary genetic determinant of ischemic stroke, rather than other lipid markers. However, its predictive value for the recurrence of non-cardioembolic acute ischemic stroke (AIS) remains unclear. This study aims to investigate this association. Methods This study recruited 578 patients with acute ischemic stroke, excluding those with cardiogenic embolism. After a 3-year follow-up, a total of 428 patients completed the prospective cohort study. A Cox regression model was used to evaluate the association between ApoB levels at admission and the recurrence rate. Additionally, a nested case-control study was conducted by comparing blood samples collected at the time of recurrence from recurrent patients with those from non-recurrent patients. Binary logistic regression and ROC curve analysis were used to assess the association between serum ApoB, LDL-C, and stroke recurrence at the time of recurrence. Results The Cox regression model demonstrated that ApoB levels upon admission were an independent predictor of stroke recurrence (HR=6.697; 95% CI: 2.581-17.374, P<0.001). Patients with recurrent strokes exhibited significantly higher serum ApoB levels at admission compared to those without recurrence [0.85 g/L (IQR=0.21) vs. 0.63 g/L (IQR=0.15)]. In the ROC receiver curve, ApoB demonstrated a higher ability to identify stroke recurrence compared with LDL-C (AUC=0.732). Conclusion Higher serum ApoB levels increase the risk of recurrence in patients with non-cardiac AIS, and ApoB has demonstrated better predictive value compared with LDL-C after drug therapy. These findings suggest that routine ApoB measurement may optimize secondary stroke prevention.
Files
Steps to reproduce
All data were obtained by trained clinicians, and hospitalized patients had hospital records.